Clinical Significance of HER2 and EGFR Expression in Colorectal Cancer Patients with Ovarian Metastasis

Overview

Journal BMC Clin Pathol

Publisher Biomed Central

Date 2019 Mar 13

PMID 30858756

Citations 10

Authors

Ji-Lin Li

Shu-Han Lin

Hong-Qiu Chen

Li-Sheng Liang

Xian-Wei Mo

Hao Lai

Jie Zhang

Jing Xu

Bing-Qian Gao

Yan Feng

Yuan Lin

Affiliations

Soon will be listed here.

Abstract

Background: EGFR and HER2 overexpression has been reported to play important roles in colorectal cancer (CRC) development and metastasis. Ovarian metastasis is rare yet is one of the most malignant metastases of CRC, but very few studies have focused on its biological features. This study aimed to investigate the expression of EGFR and HER2 in ovarian metastases of CRC and to reveal their clinical significance.

Methods: The expression of HER2 and EGFR in both primary tumours and ovarian metastases was analysed by immunohistochemistry (IHC) in 31 CRC patients with ovarian metastases as well as in the primary tumours of 26 CRC patients with non-ovarian metastases. The overall survival time was calculated with a Kaplan-Meier survival curve and compared with a log-rank test.

Results: HER2 positivity in primary tumours was significantly higher in patients with ovarian metastases than in those with non-ovarian metastases (54.5% vs. 36.4%, < 0.05). The EGFR-positive rate in primary lesions was not significantly different between patients with ovarian metastases and those with non-ovarian metastases (63.6% vs. 58.3%, > 0.05). HER2 expression was not correlated with age, primary tumour site, tumour differentiation, tumour diameter or vascular cancer embolus ( > 0.05). The positive rates of HER2 and EGFR in ovarian metastases were 44.8 and 69.0%, respectively. HER2 expression in ovarian metastases was correlated with peritoneal metastasis and bilateral ovarian metastasis ( < 0.05) but not with age, synchronous or metachronous ovarian metastases and the primary tumour site ( > 0.05). There was no significant correlation between EGFR expression and the clinicopathological features in ovarian metastases ( > 0.05). CRC patients with HER2-positive ovarian metastases showed a shortened overall survival time compared to that of CRC patients with HER2-negative metastases (17.0 ± 5.2 vs. 32.0 ± 8.3 months).

Conclusion: Our studies revealed that EGFR and HER2 are highly expressed in the primary tumours and metastases of CRC patients with ovarian metastases. HER2 positivity may be a negative prognostic predictor in patients with ovarian metastases.

Citing Articles

Genomic profiling of colorectal cancer in large-scale Chinese patients: amplification and somatic mutations in ERBB2.

Liu Y, Bischof E, Chen Z, Zhou J, Zhang B, Zhang D Oncol Res. 2024; 32(9):1429-1438.

PMID: 39220126 PMC: 11361911. DOI: 10.32604/or.2024.047309.

A Novel Dual-Payload ADC for the Treatment of HER2+ Breast and Colon Cancer.

Mckertish C, Kayser V Pharmaceutics. 2023; 15(8).

PMID: 37631234 PMC: 10459570. DOI: 10.3390/pharmaceutics15082020.

Development of Lu-Cetuximab-PAMAM dendrimeric nanosystem: a novel theranostic radioimmunoconjugate.

Hosseini S, Mohammadnejad J, Yousefnia H, Alirezapour B, Rezayan A J Cancer Res Clin Oncol. 2023; 149(10):7779-7791.

PMID: 37029816 DOI: 10.1007/s00432-023-04724-z.

Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer.

Dazio G, Epistolio S, Frattini M, Saletti P J Clin Med. 2022; 11(24).

PMID: 36556139 PMC: 9783354. DOI: 10.3390/jcm11247523.

Precision Medicine in Metastatic Colorectal Cancer: Targeting ERBB2 (HER-2) Oncogene.

Torres-Jimenez J, Esteban-Villarrubia J, Ferreiro-Monteagudo R Cancers (Basel). 2022; 14(15).

PMID: 35954382 PMC: 9367374. DOI: 10.3390/cancers14153718.

References

Olayioye M, Neve R, Lane H, Hynes N . The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000; 19(13):3159-67. PMC: 313958. DOI: 10.1093/emboj/19.13.3159. View

Bibeau F, Boissiere-Michot F, Sabourin J, Gourgou-Bourgade S, Radal M, Penault-Llorca F . Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray. Virchows Arch. 2006; 449(3):281-7. PMC: 1888717. DOI: 10.1007/s00428-006-0247-9. View

Cappuzzo F, Finocchiaro G, Rossi E, Janne P, Carnaghi C, Calandri C . EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol. 2007; 19(4):717-23. DOI: 10.1093/annonc/mdm492. View

Lee S, Lee J, Lim H, Kang W, Choi C, Lee J . Survival benefit from ovarian metastatectomy in colorectal cancer patients with ovarian metastasis: a retrospective analysis. Cancer Chemother Pharmacol. 2009; 66(2):229-35. DOI: 10.1007/s00280-009-1150-2. View

Rego R, Foster N, Smyrk T, Le M, Oconnell M, Sargent D . Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br J Cancer. 2009; 102(1):165-72. PMC: 2813748. DOI: 10.1038/sj.bjc.6605473. View

Kruszewski W, Rzepko R, Ciesielski M, Szefel J, Zielinski J, Szajewski M . Expression of HER2 in colorectal cancer does not correlate with prognosis. Dis Markers. 2011; 29(5):207-12. PMC: 3835377. DOI: 10.3233/DMA-2010-0742. View

Lee W, Baek J, Lee J, Lee W . Mutations in K-ras and epidermal growth factor receptor expression in Korean patients with stages III and IV colorectal cancer. Int J Surg Pathol. 2011; 19(2):145-51. DOI: 10.1177/1066896911400411. View

Ruschoff J, Hanna W, Bilous M, Hofmann M, Osamura R, Penault-Llorca F . HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012; 25(5):637-50. DOI: 10.1038/modpathol.2011.198. View

Li W, Wang H, Wang J, L V F, Zhu X, Wang Z . Ovarian metastases resection from extragenital primary sites: outcome and prognostic factor analysis of 147 patients. BMC Cancer. 2012; 12:278. PMC: 3487894. DOI: 10.1186/1471-2407-12-278. View

10.

Martin V, Landi L, Molinari F, Fountzilas G, Geva R, Riva A . HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. Br J Cancer. 2013; 108(3):668-75. PMC: 3593567. DOI: 10.1038/bjc.2013.4. View

11.

Feng Q, Pei W, Zheng Z, Bi J, Yuan X . Clinicopathologic characteristics and prognostic factors of 63 gastric cancer patients with metachronous ovarian metastasis. Cancer Biol Med. 2013; 10(2):86-91. PMC: 3719191. DOI: 10.7497/j.issn.2095-3941.2013.02.004. View

12.

Siegel R, DeSantis C, Jemal A . Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014; 64(2):104-17. DOI: 10.3322/caac.21220. View

13.

Missiaglia E, Jacobs B, DArio G, Di Narzo A, Soneson C, Budinska E . Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 2014; 25(10):1995-2001. DOI: 10.1093/annonc/mdu275. View

14.

Ingold Heppner B, Behrens H, Balschun K, Haag J, Kruger S, Becker T . HER2/neu testing in primary colorectal carcinoma. Br J Cancer. 2014; 111(10):1977-84. PMC: 4229629. DOI: 10.1038/bjc.2014.483. View

15.

Valtorta E, Martino C, Sartore-Bianchi A, Penaullt-Llorca F, Viale G, Risio M . Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol. 2015; 28(11):1481-91. DOI: 10.1038/modpathol.2015.98. View

16.

Richman S, Southward K, Chambers P, Cross D, Barrett J, Hemmings G . HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol. 2015; 238(4):562-70. PMC: 4785607. DOI: 10.1002/path.4679. View

17.

Nam S, Yun S, Koh J, Kwak Y, Seo A, Park K . BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis. PLoS One. 2016; 11(3):e0151865. PMC: 4798471. DOI: 10.1371/journal.pone.0151865. View

18.

Siena S, Sartore-Bianchi A, Marsoni S, Hurwitz H, McCall S, Penault-Llorca F . Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann Oncol. 2018; 29(5):1108-1119. PMC: 5961091. DOI: 10.1093/annonc/mdy100. View

19.

Sawada K, Nakamura Y, Yamanaka T, Kuboki Y, Yamaguchi D, Yuki S . Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2018; 17(3):198-205. DOI: 10.1016/j.clcc.2018.05.006. View

20.

Shan L, Lv Y, Bai B, Huang X, Zhu H . Variability in HER2 expression between primary colorectal cancer and corresponding metastases. J Cancer Res Clin Oncol. 2018; 144(11):2275-2281. DOI: 10.1007/s00432-018-2744-z. View